Users Online: 764 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 


RSACP wishes to inform that it shall be discontinuing the dispatch of print copy of JOACP to it's Life members. The print copy of JOACP will be posted only to those life members who send us a written confirmation for continuation of print copy.
Kindly email your affirmation for print copies to [email protected] preferably by 30th June 2019.

 
CLINICAL PHARMACOLOGY
Year : 2020  |  Volume : 36  |  Issue : 1  |  Page : 104-109

Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention


1 Department of Anesthesia and Pain Medicine, Division of Headache Medicine, University of Cincinnati, Cincinnati, Ohio, USA
2 Department of Internal Medicine, Division of Headache Medicine, University of Cincinnati, Cincinnati, Ohio, USA
3 Department of Neurology and Rehab Medicine, Division of Headache Medicine, University of Cincinnati, Cincinnati, Ohio, USA

Correspondence Address:
Dr. Shuchita Garg
Department of Anesthesia and Pain Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joacp.JOACP_3_19

Rights and Permissions

Headaches and migraines continue to be a leading cause of suffering and disability. As per the Global Burden of Disease Survey conducted in 2010, the exact magnitude of the disease still is underestimated. Migraine alone continues to rank seventh as a cause of disability. Various therapeutic modalities exist and newer classes of medications are currently being trialed to provide effective treatment to this population of patients. Erenumab, a calcitonin gene-related peptide receptor inhibitor, is a recent addition to this armamentarium and has been approved by the FDA for use in 2018. It has shown modestly improved outcomes according to the current trials. However, long-term outcomes and adverse effects still are under research. The following article elaborates on the current literature and evidence on this novel drug.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed993    
    Printed24    
    Emailed0    
    PDF Downloaded160    
    Comments [Add]    

Recommend this journal